The Human Microbiome Market witnesses substantial market growth due to the increased emphasis of pharmaceutical companies, research organizations, and healthcare organizations on therapies, diagnostics, and personalized nutrition based on microbial communities. The rising prevalence of obesity, diabetes, and autoimmune diseases and the advances made in the field of genomics and sequencing technologies are changing the way microbiome sciences are being commercialized as therapy and diagnostics.
The global Human Microbiome Market size is projected to reach USD 7.66 Billion by 2035 from USD 1.39 Billion in 2025, at a CAGR of 18.62% from 2026 to 2035. Various factors are driving growth in the Human Microbiome Market including the advancement in genomic sequencing technologies, integration of personalized nutrition and microbiome therapeutics, growing clinical trials for metabolic and autoimmune disease indications, and growing probiotics and prebiotics product launches globally.
Gain Actionable Intelligence on the Human Microbiome Market - Request a Sample Report
Key Players
Some of the major companies operating in the Human Microbiome Market are Seres Therapeutics, Ferring Pharmaceuticals, Nestlé Health Science, Seed Health, Finch Therapeutics, Vedanta Biosciences, Synlogic, Assembly Biosciences, Eligo Bioscience, Locus Biosciences, Microba Life Sciences, Viome Life Sciences, MaaT Pharma, BioGaia, and others.
Strategic Developments & Industry Innovations
- Seres Therapeutics presented expanded biomarker data in May 2025 from its SER-155 Phase 1b study, supporting microbiome-based therapeutics for gut health.
- Ferring Pharmaceuticals expanded manufacturing capacity in April 2025 for Rebyota and ADSTILADRIN®, addressing rising demand for microbiome therapies.
- Nestlé reported growth in July 2025 in its microbiome product portfolio, including Vowst and probiotics, across Europe and Asia.
Top Players Driving Innovation in the Human Microbiome Market:
1. Seres Therapeutics: Pioneering Live Biotherapeutic Products
Seres Therapeutics is one of the top companies in microbiome therapeutics due to having conducted over 320 clinical studies for microbiome-based therapies such as Vowst, the world’s first oral microbiota-based therapy for recurrent C. difficile infections, in 2025. It is conducting the largest number of clinical studies in microbiome therapeutic platform in the world with over 8,500 patients being enrolled in its clinical trials.
2. Ferring Pharmaceuticals: Strengthening Fecal Microbiota Therapy Leadership
AFerring Pharmaceuticals expands into microbiome drug development and therapeutic - Rebiotix is a leader in the discovery and development of live biotherapeutic products. Its Rebyota treatment was given to over 6,200 patients in North America and Europe in 2025. Ferring continue to establish its leadership position in the field, managing 215 microbiome research programs & numerous academic partnerships across the globe.
3. Nestlé Health Science: Expanding Microbiome-Based Nutrition Solutions
Nestlé Health Science has been able to diversify itself into the area of the microbiome through its acquisition of Vowst technology from Seres Therapeutics, offering products based on the microbiome through 12 different products for Europe and Asia in 2025, serving more than 4,500 patients. With further innovation and partnerships with biotech start-ups, Nestlé is still a leader in microbiome health solutions.
Advancing Precision Health Through Innovation in the Human Microbiome Market
Consistent growth in the Human Microbiome Market is anticipated on account of the usage of genomic sequencing, personal nutrition plans, and live biotherapeutic products in the pharma and biotech industry. The market will witness growth owing to advancements in the field of metabolomics technology, autoimmune disease studies, and diagnostics.
Key players in the market include Seres Therapeutics, Ferring Pharmaceuticals, and Nestlé Health Science. They have been driving innovation in the industry through clinically validated therapeutics, expanding manufacturing capacity, and strategic research collaborations. With healthcare providers becoming more concerned about precision medicine and gut health outcomes, the human microbiome will continue to play an essential part in the future of personalized healthcare.
